- Coordinator
- Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
- Runs
- 1 January 2027 to 31 December 2030
- Status
- Running
- EU funding
- €3.3m
- Total cost
- —
- Partners
- 22 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311289
What the project is doing
In the project's own words, from its summary on CORDIS.
Targeted Protein Degradation (TPD), an innovative strategy to redirect the cellular degradation machinery towards the elimination of disease-relevant proteins, has attracted enormous attention from researchers, industry and clinicians. TPD is based on the capacity of a small molecule, the degrader, to re-route the ubiquitination machinery towards a selected protein of interest to trigger its ubiquitination and degradation by the Ubiquitin Proteasomal System, via its interaction with specific E3 ubiquitin ligases.
ProofReading will bring together a diverse community, assembling the necessary multidisciplinary expertise to develop novel TPD approaches applicable to various cellular and disease contexts, facilitating the generation of degraders. ProofReading will establish an interdisciplinary, intersectoral and international research programme to drive the development of tools, degraders and innovative strategies aimed at eliminating targets involved in cancer, infection, inflammation and rare diseases.
The network comprises 10 universities, 4 research centres and 8 innovative companies, which will provide state-of-the-art training for the recruited Doctoral Candidates (DCs). This is the only doctoral network related to proteome proofreading by using TPD that combines the knowledge in all disciplines, ranging from life to physical sciences, required to develop a degrader. Interdisciplinary and intersectoral secondments will expose the DCs to different working environments.
We will organize 5 hands-on research workshops on central methodological and technical aspects of TPD and 7 courses on transferable skills, of primary importance for increasing the employability of the DCs. We will also address the important issue of mental health and well-being in science. ProofReading will train 11 researchers with specific knowledge in the cutting-edge technology of TPD, which will contribute to the generation of future drugs to treat diseases.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune | Derio Vizcaya | Spain | Coordinator |
| Forschungsinstitut Fur Molekulare Pathologie Gesellschaft Mbh | Wien | Austria | Participant |
| Proxygen GmbH | Vienna | Austria | Associatedpartner |
| Universitat Wien | Wien | Austria | Associatedpartner |
| Vrije Universiteit Brussel | Bruxelles / Brussel | Belgium | Associatedpartner |
| Ecole Polytechnique Federale De Lausanne | Lausanne | Switzerland | Participant |
| Bruker Daltonics GmbH & Co Kg | Bremen | Germany | Participant |
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Participant |
| Philipps Universitaet Marburg | Marburg | Germany | Participant |
| Technische Universitaet Dresden | Dresden | Germany | Associatedpartner |
| Atlas Molecular Pharma SL | Derio | Spain | Associatedpartner |
| Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | Badalona | Spain | Associatedpartner |
| Norarte Visual Science SL | Abadiño | Spain | Associatedpartner |
| Oniria Therapeutics SL | Barcelona | Spain | Associatedpartner |
| Sofia Maria Facal Belli | San Sebastián- Donosti | Spain | Associatedpartner |
| Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea | Leioa | Spain | Associatedpartner |
| Universitat De Barcelona | Barcelona | Spain | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Hybrigenics Services | Evry-Courcouronnes | France | Associatedpartner |
| Universite De Toulouse | Toulouse | France | Associatedpartner |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI